Log In
Print
BCIQ
Print
Print this Print this
 

CERC-301, MK-0657

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionSmall molecule NMDA receptor NR2B subtype (GRIN2B; NR2B; GluN2B) antagonist
Molecular Target NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B)
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationDepression
Indication DetailsTreat depression; Treat major depressive disorder (MDD); Treat suicidality
Regulatory Designation

U.S. - Fast Track (Treat major depressive disorder (MDD))

Partner

Cerecor Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today